CL2012000247A1 - Composicion farmaceutica que comprende un agente quimioterapeutico y un oligonucleotido antisentido contra tgf beta. - Google Patents
Composicion farmaceutica que comprende un agente quimioterapeutico y un oligonucleotido antisentido contra tgf beta.Info
- Publication number
- CL2012000247A1 CL2012000247A1 CL2012000247A CL2012000247A CL2012000247A1 CL 2012000247 A1 CL2012000247 A1 CL 2012000247A1 CL 2012000247 A CL2012000247 A CL 2012000247A CL 2012000247 A CL2012000247 A CL 2012000247A CL 2012000247 A1 CL2012000247 A1 CL 2012000247A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- chemotherapeutic agent
- antisense oligonucleotide
- tgf beta
- oligonucleotide against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Abstract
Composición farmacéutica que comprende un agente quimioterapéutico y un oligonucleótido antisentido contra TGF beta.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09166893 | 2009-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012000247A1 true CL2012000247A1 (es) | 2013-07-05 |
Family
ID=41278403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012000247A CL2012000247A1 (es) | 2009-07-30 | 2012-01-30 | Composicion farmaceutica que comprende un agente quimioterapeutico y un oligonucleotido antisentido contra tgf beta. |
Country Status (17)
Country | Link |
---|---|
US (1) | US8476246B2 (es) |
EP (1) | EP2340308B1 (es) |
JP (1) | JP2013500313A (es) |
KR (1) | KR20120107456A (es) |
CN (1) | CN102712924A (es) |
AU (1) | AU2010277554B2 (es) |
BR (1) | BR112012002102A2 (es) |
CA (1) | CA2769618A1 (es) |
CL (1) | CL2012000247A1 (es) |
CO (1) | CO6511199A2 (es) |
EC (1) | ECSP12011689A (es) |
IL (1) | IL217821A0 (es) |
IN (1) | IN2012DN00969A (es) |
MX (1) | MX2012001244A (es) |
PE (1) | PE20121495A1 (es) |
RU (1) | RU2012107535A (es) |
WO (1) | WO2011012713A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030158143A1 (en) * | 2002-01-17 | 2003-08-21 | Martin Gleave | Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same |
WO2012048113A2 (en) | 2010-10-07 | 2012-04-12 | The General Hospital Corporation | Biomarkers of cancer |
TWI454281B (zh) * | 2011-10-06 | 2014-10-01 | Nat Univ Tsing Hua | 硼酸於硼中子捕獲治療肝癌之用途 |
WO2013124869A2 (en) * | 2012-02-21 | 2013-08-29 | Amrita Vishwa Vidyapeetham University | The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations |
US20140275214A1 (en) * | 2013-03-14 | 2014-09-18 | Teva Pharmaceutical Industries, Ltd. | Custirsen treatment with reduced toxicity |
EP3146334B1 (en) * | 2014-05-23 | 2019-08-14 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for determining whether a patient will achieve a response after radiation therapy |
WO2016081503A1 (en) * | 2014-11-17 | 2016-05-26 | City Of Hope | Tki permeability enhancers |
EP3314250A4 (en) | 2015-06-26 | 2018-12-05 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
KR101843985B1 (ko) | 2016-02-09 | 2018-03-30 | 오토텔릭 엘엘씨 | 암을 치료하기 위한 조성물과 방법 |
WO2017138924A1 (en) | 2016-02-09 | 2017-08-17 | Autotelic Llc | Compositions and methods for treating pancreatic cancer |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
EP3532638A4 (en) | 2016-10-31 | 2020-07-29 | University of Massachusetts | TARGETING MICROARN-101-3 P IN CARCINOTHERAPY |
WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
CA3090652A1 (en) | 2018-02-06 | 2019-08-15 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
AU2020237255A1 (en) * | 2019-03-14 | 2021-09-09 | The Research Foundation For The State University Of New York | Modified micrornas and their use in the treatment of cancer |
GB201908012D0 (en) * | 2019-06-05 | 2019-07-17 | Io Biotech Aps | TGF-Beta vaccine |
CN112933238A (zh) * | 2021-02-02 | 2021-06-11 | 石河子大学 | 抑制TGF-βR1基因表达的物质与顺铂在治疗和/或预防食管癌中的应用 |
CN113425855B (zh) * | 2021-06-28 | 2023-11-07 | 深圳瑞吉生物科技有限公司 | 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
WO1983001451A1 (en) | 1981-10-23 | 1983-04-28 | Molecular Biosystems Inc | Oligonucleotide therapeutic agent and methods of making same |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
EP0856579A1 (en) * | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | An antisense oligonucleotide preparation method |
US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
US6809118B2 (en) * | 2002-07-25 | 2004-10-26 | Yih-Lin Chung | Methods for therapy of radiation cutaneous syndrome |
CN1845733A (zh) * | 2003-09-04 | 2006-10-11 | 学校法人日本大学 | TGF-β基因表达抑制剂 |
CA2542215A1 (en) * | 2003-11-13 | 2005-06-02 | Genentech, Inc. | Screening assays and methods of tumor treatment |
CN1902488A (zh) * | 2003-11-13 | 2007-01-24 | 健泰科生物技术公司 | 肿瘤治疗的筛选实验和方法 |
AU2004299670B2 (en) * | 2003-12-19 | 2010-04-22 | Antisense Pharma Gmbh | Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent |
US20070155685A1 (en) * | 2004-02-27 | 2007-07-05 | Karl-Hermann Schlingensiepen | Pharmaceutical composition |
JPWO2007088651A1 (ja) * | 2006-02-01 | 2009-06-25 | 国立大学法人 東京大学 | TGF−βシグナル阻害剤と抗腫瘍剤の組み合せ使用 |
JP5322476B2 (ja) * | 2008-03-31 | 2013-10-23 | テルモ株式会社 | リポソームの製造装置およびリポソームの製造方法 |
-
2010
- 2010-07-30 AU AU2010277554A patent/AU2010277554B2/en not_active Ceased
- 2010-07-30 MX MX2012001244A patent/MX2012001244A/es active IP Right Grant
- 2010-07-30 US US13/059,623 patent/US8476246B2/en active Active
- 2010-07-30 WO PCT/EP2010/061152 patent/WO2011012713A1/en active Application Filing
- 2010-07-30 JP JP2012522185A patent/JP2013500313A/ja active Pending
- 2010-07-30 RU RU2012107535/15A patent/RU2012107535A/ru not_active Application Discontinuation
- 2010-07-30 PE PE2012000130A patent/PE20121495A1/es not_active Application Discontinuation
- 2010-07-30 CN CN2010800436805A patent/CN102712924A/zh active Pending
- 2010-07-30 CA CA2769618A patent/CA2769618A1/en not_active Abandoned
- 2010-07-30 IN IN969DEN2012 patent/IN2012DN00969A/en unknown
- 2010-07-30 KR KR1020127005337A patent/KR20120107456A/ko not_active Application Discontinuation
- 2010-07-30 EP EP10737580.0A patent/EP2340308B1/en not_active Not-in-force
- 2010-07-30 BR BR112012002102A patent/BR112012002102A2/pt not_active IP Right Cessation
-
2012
- 2012-01-29 IL IL217821A patent/IL217821A0/en unknown
- 2012-01-30 CL CL2012000247A patent/CL2012000247A1/es unknown
- 2012-02-23 EC ECSP12011689 patent/ECSP12011689A/es unknown
- 2012-02-29 CO CO12035227A patent/CO6511199A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL217821A0 (en) | 2012-03-29 |
PE20121495A1 (es) | 2012-11-19 |
US8476246B2 (en) | 2013-07-02 |
CN102712924A (zh) | 2012-10-03 |
IN2012DN00969A (es) | 2015-04-10 |
RU2012107535A (ru) | 2013-09-10 |
AU2010277554A1 (en) | 2012-03-01 |
KR20120107456A (ko) | 2012-10-02 |
AU2010277554B2 (en) | 2015-02-19 |
BR112012002102A2 (pt) | 2017-05-02 |
JP2013500313A (ja) | 2013-01-07 |
MX2012001244A (es) | 2012-03-26 |
US20120027873A1 (en) | 2012-02-02 |
EP2340308B1 (en) | 2014-12-24 |
CO6511199A2 (es) | 2012-08-31 |
CA2769618A1 (en) | 2011-02-03 |
WO2011012713A1 (en) | 2011-02-03 |
ECSP12011689A (es) | 2012-06-29 |
EP2340308A1 (en) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012000247A1 (es) | Composicion farmaceutica que comprende un agente quimioterapeutico y un oligonucleotido antisentido contra tgf beta. | |
BRPI0923823A2 (pt) | Agente de colaboração. | |
GB0823716D0 (en) | Stent delivery device with rolling stent retaining sheath | |
MX2011013421A (es) | Arnds formulado con lipido de direccionamiento del gen pcsk9. | |
BR112012010676A2 (pt) | partícula de alta eficiência que compreende um agente de benefício. | |
IN2012DN01869A (es) | ||
EP2366785A4 (en) | OLIGONUCLEOTIDE DERIVATIVES, MARKING AGENTS AND THE MARKETING AGENT | |
CO6910187A2 (es) | Composiciones parasiticidas que comprenden un agente activo isoxazolina, sus métodos y usos | |
NZ797319A (en) | Modified rnai agents | |
BRPI1014139A2 (pt) | sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo. | |
HK1156071A1 (en) | Buttiauxella sp. phytase variants | |
GEP20156329B (en) | CHEMICAL MODIFICATIONS OF miRNA INHIBITORS AND MIMETICS | |
IL206932A0 (en) | Devices, formulations, and methods for delivery of multiple beneficial agents | |
CL2011001811A1 (es) | Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico. | |
CL2011002595A1 (es) | Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion. | |
BR112012000530A2 (pt) | uso de uma população de nanopartículas metálicas, e, composição farmacêutica. | |
CR20110002S (es) | Barra de chocolate | |
MX2009009468A (es) | Ensamble de tampon que tiene una almohadilla moldeada. | |
BRPI1016194A2 (pt) | Composição inseticida que compreende uma espinosina e um óxido de metal. | |
CL2013000762A1 (es) | Composicion que comprende a) una particula de entrega de agente benefico que comprende poli-xiloglucano o poli-galactomanana y b) una mananasa. | |
BR112012008504A2 (pt) | composição para entrega de agente ativo com carboidrato aprisionado e artigos usando a mesma | |
PH12010000212A1 (en) | Absorbent article including absorbent core having a plurality of first regions and a second region surrounding each of the first regions | |
BR112012004967A2 (pt) | forma de dosagem oral, compreendendo pelo menos um agente biologicamente ativo, substâncias auxiliares da formulação e partículas magnetizáveis | |
BRPI0910912A2 (pt) | Composto, prodroga, ativador de glicocinase, agente farmacêutico, e, uso do composto | |
PH12014502858A1 (en) | Racecadotril lipid compositions |